Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o. - levodopa, inhibítor dekarboxylázy a comt inhibítor - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

jazz pharmaceuticals ireland ltd, Írsko - kanabinoidy - 63 - myorelaxantia

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ziaja ltd zakład produkcji leków sp. z o.o., poľsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica

Európska únia - slovenčina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Európska únia - slovenčina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lobsor pharmaceuticals ab, Švédsko - levodopa, inhibítor dekarboxylázy a comt inhibítor - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

coloplast a/s holtedam 1 humlebaek dánsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

coloplast a/s holtedam 1 humlebaek dánsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

coloplast a/s holtedam 1 humlebaek dánsko -